Improving China cancer epidemiology : combining market research and public cancer registry, with IPSOS Healthcare and L.E.K

November 2021

CphMRa conference 2021

In partnership with dream

Let me introduce myself



- Full career in Market Research and Data Management for over 20 years.
- Graduate of leading French ESSEC Business School
- Worked from Agency to Industry leaders, from FMCG to Pharmaceutical (Rx/OTC), in France, Switzerland, Japan and China, from country affiliate to Regional or Global Headquarters.
- Extensive knowledge of Pharmaceutical Market Research data sources

Volunteer Analytics Lead of Solidarity Covid – Expats in China, Daily Analysis live from Shanghai on Covid-19 China and worldwide public data. https://deeperin19coviddata.wordpress.com/

My career in a matrix...

Italic : Consultancy assignment

	France (age 3-2007)	Japan (2007-2010)	Switzerland (2010-2013)	China Since 2013
FMCG country	Gillette (P&G) – 2000-2002 <i>CPC (Unilever)</i> 1993			
FMCG research agency	Nielsen 1994-1999			
Pharma country		Bayer Schering Pharma (2007- 2010)		Sanofi (2015-2016)
Pharma Region & Global	Bristol-Myers Squibb (2003-2007)		Novartis Pharma (2010-2011) Vifor Pharma (2011- 2015)	
Pharma research agency				Cegedim Strategic data (2014) IPSOS Healthcare (2015-2016)

Over all these years, I developed smart analysis tools on recurrent market research, recently on Oncology in China

An exclusive Instant Analytics tool displaying instantly 90% of the metrics collected in the patient card, with a drop down on the period, Diagnosis, Molecule or regimen

			Diagnosis		Brand	or Molecule	Wave	previous	wave											
China 🛛		choose	Breast	*		7	MAT 20165	MAT 2015	551	1										
		Diagnosi s here		-	_		choose	choos	e time											
			Molecule selec	tion criteria	امک	ected	molecule	cnoos	e ame											
					501															
		cancer type	solid turnor	Molecule	mo	lecule	category	PLANT A	LKALOIDS	3	NON-HO	DRMONE								
		Main site	Breast											aspa	rt of regim	en (short l	Name if any) nb patien	s	
Markat	t dynamics An	alucie			Main	Diagnosis		colocte	ed molecu	lo.			DP							
laiket								Selecte	Share	ne -										
					nbof	distribution	nbof	distributi	Onare Main	diff vs	%	% of income								
						of patients	patients	on of	Diagnosi	prev.	original	>10000		Regin	iens li	nc. Se	elected	molec	uie	
					patients	orpatients	patients	patients	s	wave	brand	RMB								
					2024	100.01/	770	100.01/	20.4	5.0	101/			445			1 100	440		
Breast	Easter at a sec				2024 1500		778	100.0%	38.4 7.0	5.9 -26.7	16% 15%	2% 1%	21 9	115	12		1 132 120		87 77	8
	Early stage Early Stage Di	rug Therapy		early early	56		21	2.7%	37.5	-26.7	52%	5%	3	6	0		120		1	1
	Neo-Adjuvan			early	132		61	7.8%	46.2	12.4	15%	7%	1	8			15		11	
	Adjuvant ther			early	1269		530	68.1%	41.8	7.9	14%	9%	8	85	6		102		64	
	Late stage	467		late	523		153		29.3	-0.6	20%	6%	12	14	4		1 12		10	
	Met 1st Line			1	278		95		34.2	0.7	127	7%	4	9	2		6			
	Met 2nd Line			2	192		53		27.6	2.6	36%	4%	8	5	2		1 4	4	1	
	Met 3rd line			3	40	2.0%	5	0.6%	12.5	-1.3							2			
	Met 4th line			4	7															
	Met 5th line			5	5					-14.3										
1	late 2+ line				245	12.1%	58	7.5%	23.7	0.7	33%	3%	8	5	2		1 6	4	1	
	274		N RAN	******		8294				Most rele	evant tes	st for Diagno	osis site	Main D)iagnosis sit	te	patie	nts on select	ed molecu	le
		100 A		1.20-44		and the second	+10.0						+		share on .	diff			Share	diff
		火性	18.7%									HER2 type						share on	on Main	charou
	20.75	- 灾牲 • 两性	ix.m	+ 451-74	1	15.25	1 160	12.0			Q6364			nb pts	parent :	share vs	nb pts		-	
	99.2%		Contraction of the local division of the loc	+ 49 - 76 + 28 - 34		110	- 864	120			Q63 64	nichz (ype		nb pts	parent row	share vs PW	nb pts	parentrow	Diagnosi	PW
	99.2%		ix.m			R.B.	- 64	tz#			Q63 64 total			nb pts			nb pts		Diagnosi s 38.4	PW
	98.2%	-Rt	ix.m	13.1	8学分类	_		·三世 英政分布				1		·		PW 302	•		s 38.4	PW
	100 toos # 7	=用性)就双讲分	ix.m	13.1						% tested	tota teste by s	ed pecialty	-	2024	row 86.7	PW 302 3.9	- 778 671	86.2	s 38.4	PW 2 5.
	100 tcos # 7	-Rt	ix.m	ran-au Mai	創学分类					Brea	tota teste by sj ast Disease	ed pecialty e Specialist	-	2024	row 86.7 90%	PW 302 3.9 0.0	778 671 90%	1 86.2	s 38.4	PW 2 5. 0.
	152 toos # #	 - 用性 - 用性 - 数元神分 - EC014 	ix.m	• 28 - 55 560 • 34010	8学分类					Brea Inter	total teste by sj ast Disease nal Oncole	l ed pecialty e Specialist ogy		2024	row 86.7 90% 88%	PW 302 3.9 0.0 0.1	778 671 90% 85%	86.2	s 38.4	PW 2 5. 0. 0.
	122 COG # 7	•周性 	ix.m	• 28 - 55 500 • 4 acta • 3 acta	创学分类 arciverte					Brea Inter	total teste by sj ast Disease nal Oncole eral/colore	ed pecialty e Specialist ogy ectal surgeon		2024	row 86.7 90%	PW 302 3.9 0.0 0.1	778 671 90%	86.2	s 38.4	PW 2 5. 0.
	100 1000 # /1 1235	•周性 10.22.04 分 - EC014 - EC00 3 - EC00 2	ix.m	- 20-20 - 5400 - 5400 - 5400	8学分类 					Brea Inter Gen	total teste by sj ast Disease nal Oncole eral/colore	ed pecialty e Specialist ogy ectal surgeon e and line ed	-	2024 1755 1755	row 86.7 90% 88% 75% 86.7	PW 302 3.9 0.0 0.1 0.0 3.9	778 671 90% 85% 77%	- 86.2	2 38.2 2 38.2	PW 2 5. 0. 0. 2 5.
	122 toos 16 7	•用性 10.22.04 分 = 80.01 4 = 60.06 3 = 60.06 2 = 80.06 4	ix.m	- 20-20 - 5400 - 5400 - 5400	8学分类 		P RA	并最分布		Brea Inter Gen all specialtie	total teste by sj ast Disease nal Oncole eral/colore s by stage	ed ed speciality ectal surgeon e and line ed HER2+		2024 1755 1755 1755 378	row 86.7 90% 88% 75% 86.7 21.5	PW 302 3.9 0.0 0.1 0.0 3.9 -2.0	778 671 90% 85% 77% 671 155	- 86.2 86.2 86.2	38.4 2 38.2 2 38.2 2 38.2 1 41.0	PW 2 5. 0. 0. 0. 2 5. 33.
	100 1000 # /1 1235	•用性 10.22.04 分 = 80.01 4 = 60.06 3 = 60.06 2 = 80.06 4	ix.m	- 20-20 - 20-20 - 20-20 - 20-20 - 20-20 - 20-20	8学分类 			并最分布		Brea Inter Gen all specialtie	total teste by sj ast Disease nal Oncole eral/colore so by stage teste	ed ed speciality e Specialist ogy ectal surgeon e and line ed HER2+ HER2-		2024 1755 1755 378 1083	row 86.7 90% 88% 75% 86.7 215 61.7	PW 302 3.9 0.0 0.1 0.0 3.9 -2.0 2.2	778 671 90% 85% 77% 671 155 402	86.2 86.2 86.2 23. 5 23.	2 38.2 2 38.2 2 38.2 1 41.0 3 37.1	PW 2 5. 0. 0. 0. 2 5. 33. 1 19.
	100 1000 (b.f) 1235 1235 1235	- 現住 - 民のは - ECOG 4 - ECOG 4 - ECOG 4 - ECOG 5 - ECOG 5 - ECOG 6 - ECOG 7 - ECO	ix.m	- 20-20 - 20-20 - 20-20 - 20-20 - 20-20 - 20-20	8学分类 		P RA	并最分布	ł	Brea Inter Ger all specialtic cotal	total testa by sj ast Disease nal Oncole eral/colore s by stage testa	l ed l peciality e Specialist ogy ectal surgeon e and line ed HER2+ HER2+ tested		2024 1755 1755 378 1083 269	row 86.7 90% 88% 75% 86.7 21.5 61.7 13.3	PW 302 3.9 0.0 0.1 0.0 3.9 -2.0 2.2 -3.9	778 671 90% 85% 77% 671 155 402 107	86.2 86.2 86.2 86.2 1 86.2 1 8.2 1 1 8.2 1 8 1 1 8.2 1 1 8.2 1 1 1 1 8.2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2 38.2 2 38.2 2 38.2 1 41.0 3 37.1 3 39.8	PW 5. 0. 0. 5. 5. 1 33. 1 19. 33.
	100 1000 \$\$ 7 12 25 12 25 12 25	- 現住 - 民のは - ECOG 4 - ECOG 4 - ECOG 4 - ECOG 5 - ECOG 5 - ECOG 6 - ECOG 7 - ECO		- 10 - 10 - 10 - 5 or 10 -	8学分类 arcinette (#11ges 4	RAPH AND AND MARCA	P RA	并最分布	ł	Brea Inter Gen all specialtie	total teste by sj ast Disease nal Oncole eral/colore so by stage teste	l ed l peciality e Specialist ogy ectal surgeon e and line ed HER2+ HER2+ tested		2024 1755 1755 378 1083	row 86.7 90% 88% 75% 86.7 215 61.7	PW 302 3.9 0.0 0.1 0.0 3.9 -2.0 2.2 -3.9 2.0	778 671 90% 85% 77% 671 155 402	86.2 86.2 23. 59.3 13.8 86.2	38.4 2 38.2 2 38.2 1 41.0 3 37.1 3 39.8 2 41.8	PW 5. 0. 0. 5. 33. 1 19. 3 -5. 3 8.
	100 1000 (b.f) 1235 1235 1235	- 現住 - 民のは - ECOG 4 - ECOG 4 - ECOG 4 - ECOG 5 - ECOG 5 - ECOG 6 - ECOG 7 - ECO		• 28-38	B学分类 arcinuma (arcinuma (arcinuma (arcinuma (arcinuma)	A S P M A S P A S P	B <u><u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u></u></u>	并最分布	ł	Brea Inter Ger all specialtic cotal	total teste by sj ast Disease nal Oncolo eral/colore s by stage teste Not t teste	ed ed especiality especialist ogy ectal surgeon e and line ed HER2+ HER2- tested ed HER2+ HER2+ HER2-		2024 1755 378 1083 269 1291 254 811	row 86.7 30% 88% 75% 86.7 21.5 61.7 13.3 86.1 19.7 262.8	PW 302 3.9 0.0 0.1 0.0 0.1 0.0 0 0 0 0 0 0 0 0 0 0 0 0 0	778 671 90% 85% 77% 671 155 402 107 539 108 336	86.2 86.2 23. 59.5 13.6 86.2 23. 23. 23. 23. 23. 23. 23. 23. 23. 2	s 38.4 2 38.2 2 38.2 1 41.0 3 37.1 3 39.8 2 41.8 3 41.4	PW 5. 0. 0. 0. 5. 33. 1 19. 5. 8. 6. 10.
	100 1000 (b.f) 1235 1235 1235	- 現住 - 民のは - ECOG 4 - ECOG 4 - ECOG 4 - ECOG 5 - ECOG 5 - ECOG 6 - ECOG 7 - ECO		• 28-32 • 28-32 • 28-32 • 20-32 • 2	B学分类 arcinuma (arcinuma (arcinuma (arcinuma (arcinuma)	RAPH AND AND MARCA	B <u><u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u><u></u></u></u>	并最分布	ł	Brea Inter Ger all specialtic cotal	total teste by sj ast Disease nal Oncolo eral/colore s by stage teste Not t teste	ed specialist ogy ectal surgeon ectal surgeon ed HER2+ HER2+ HER2+ HER2+ tested ER2+ HER		2024 1755 1755 378 1083 269 1291 254	row 86.7 90% 88% 75% 86.7 215 61.7 13.3 86.1 13.7	PW 302 3.9 0.0 0.1 0.0 -2.0 -2.0 -2.0 -1.9 2.0 -2.0	778 671 90% 85% 77% 671 155 671 155 402 107 539 108	86.2 86.2 59.3 13.6 86.2 13.6 20.0 6.2 3 13.6	38.4 38.4 2 38.2 1 41.0 9 37.1 3 39.8 2 41.8 0 42.5 3 41.4 3 41.1	PW 5. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.

Smart analytics with customization of the group stage and the characteristics (biomarkers) by cancer type and tumor

At IPSOS I worked on Oncology market Sizing Survey in 2015


- survey on 1800 cancer treating physicians / 20 cities delivers epidemiology KPIs on all tumors
- It was intended also to compute projection factors for Oncology tracker based on patient records and tracking treatments on a 6-month / quarterly basis

On average, W	What the numbe	er of the pat	ients you hav	e treated for	each tumor
types in 1 ma	onth? And ple	ease estimate	the diagnose	d rate , trea	tment rate
and anticance	er drug treat	ment rate of e	each tumor typ	pe type? (ant	ineoplastic
drugs includi	ing: cytotoxic	e drugs, targe	eted drugs, e	ndocrine drug	s,
biological					
treatment)平均	匀而言,在一个月	日中您所治疗的每	€一种肿瘤的患者	资料目各是多少?	(填入患者人
数),并请估计	每一种肿瘤的诊	断率,治疗率,	以及肿瘤患者使	用抗肿瘤药物治纲	疗的比例各是多
			、内分泌药物、		
	2 2	03 small intestine	04 Stomach cancer	05 Faaabaawa	06 Pancreas
01 Breast cancer 乳腺癌	02 CRC结肠癌patient /	cancer小肠癌patien		05 Esophagus cancer食道癌patien	cancer胰腺癌patien
		t / month 人/月			t / month 人/月
	new patient rate其中新确诊 %	new patient rate其中新确诊 %		new patient rate其中新确诊 %	new patient rate其中新确诊 %
for the tumor.overall	for the tumor.overall	for the tumor.overall	for the tumor, overall	for the tumor.overall	for the tumor, overall
		diagnostic rate	diagnostic rate	diagnostic rate	diagnostic rate
	该肿瘤整体诊断率%			该肿瘤整体诊断率%	该肿瘤整体诊断率%
		treatment rate治疗率	treatment rate治疗率	treatment rate治疗率	treatment rate治疗率
%	%	%	%	%	%
surgical therapy	surgical therapy	surgical therapy	surgical therapy	surgical therapy	surgical therapy
rate接受手术率%	rate接受手术率%	rate接受手术率%	rate接受手术率%	rate接受手术率%	rate接受手术率%
radiotherapy	radiotherapy	radiotherapy	radiotherapy	radiotherapy	radiotherapy
rate放射治疗率%	rate放射治疗率%	rate放射治疗率%	rate放射治疗率%	rate放射治疗率%	rate放射治疗率%
	anticancer drug treatment	anticancer drug treatment	anticancer drug treatment	anticancer drug treatment	anticancer drug treatment
					rate使用抗肿瘤药物 %
	therein endocrine therapy	therein endocrine therapy	therein endocrine therapy	therein endocrine therapy	therein endocrine therapy
rate其中内分泌治疗	rate其中内分泌治疗	rate其中内分泌治疗	rate其中内分泌治疗	rate其中内分泌治疗	rate其中内分泌治疗
_%	%	%	%	%	%
targeted drugs使用靶向药物 。	targeted drugs使用靶向药物	targeted drugs使用靶向药物	targeted drugs使用靶向药物	targeted drugs使用靶向药物	targeted drugs使用靶向药物
/0	010g3(文)+3#G[0]5()+例 %	010g3(文)+3#C[0]5()+例 %	010g9(文)+3#G[0]5()+例 %	010g8j文)+3#G[0]5/]物 %	urugs(文)升#G[山]弘]初 %
	/0	/0	/0	/0	/0

(1)


2

(3)



But the global algorithms used for projection fail on China

That's how I came accross the Cancer registry



because of a large variability in the prevalence


 So a rough division of number by total coverage of 25.7% (or 27.6% for the 2019 book) will be very approximate

IPSOS Oncology Market S	izing Stud	y -1800 canc	er treating	(>8 years e	xperience)	physicia	ns 20 cities	Q4 2015 m	neasuring	patient loa	d by Diagr	nosis			
distribution of total cancer patients	Breast	Gynecologi cal	Colorect al	Hepatobi liary	Other Gastro	Lung	Prostate & Testes	Head & Neck	Urinary	Chronic leukemia	Acute leukemia	Lympho mas	Paraneop lastic	Sarcoma	Other Haemato logy
15.7% Shanghai	9.2%	4.9%	10.3%	5.0%	11.6%	12.3%	4.3%	1.3%	4.9%	5.7%	5.6%	12.4%	10.4%	0.7%	0.0%
15.7% rest of East	8.3%	9.4%	7.7%	10.3%	13.6%	15.8%	3.1%	6.8%	7.0%	2.4%	5.8%	4.4%	3.7%	0.7%	0.0%
18.1% Beijing	10.7%	6.7%	8.8%	6.9%	10.1%	17.2%	2.8%	1.4%	5.9%	3.6%	7.4%	8.7%	8.1%	0.4%	0.0%
16.0% rest of North	7.8%	5.4%	7.5%	4.2%	11.5%	35.1%	2.0%	2.0%	3.9%	2.5%	5.0%	6.8%	4.4%	0.6%	0.6%
18.1% Guangzhou	11.1%	6.6%	9.4%	4.5%	13.0%	19.7%	4.8%	4.4%	6.4%	1.5%	3.8%	5.0%	5.0%	1.2%	0.0%
1.6% rest of South	8.7%	9.5%	3.5%	9.7%	17.6%	15.5%	10.7%	5.8%	3.7%	2.3%	2.5%	5.7%	3.5%	0.5%	0.0%
23.0% West	9.2%	9.0%	5.7%	4.8%	10.6%	12.8%	3.2%	5.5%	5.5%	6.9%	10.5%	7.4%	6.2%	1.4%	0.3%
	1		1			1				-					

Tier I cities will gather more Breast patients than Tier II Tier I cities will gather more colorectal patients than Tier II

Highly polluted North cities have very high lung cancer rated - Tiering not relevant

Public cancer registry used to validate Market Sizing Study results



China cancer registry is a reference for cancer epidemiology in China now active contributor of AIRC

- Yet data is only available on paper : need to enter data
- The latest edition available covers 486 registries, covering 27.6% of total China population
- It takes about 3 years to release a cancer registry : now available 2019 book (released Jan 2021) with 2016 fieldwork
- The list of Diagnosis reported is limited to 25 key cancers for key cities

Surveillance, Center for Cancer

Control and Information

It reports incidence and mortality, so not a measurement of the actual nb of patients eligible for treatment

Lancet Article July 2020

Cancer registration in China and its role in cancer prevention 🐴 🔘 and control

Wenglang Wei", Hongmei Zeng", Rongshou Zheng", Shwei Zhang", Lan An, Ru Chen, Shaoming Wang, Kexin Sun, Tomohim Mabuda, Freddie Bruy, Jie Fir

Cancer has become a leading cause of death in China, with an increasing burden of cancer incidence and mortality Lanuel Devol 2020; 25: e342-40 observed over the past half century. Population-based cancer registries have been operating in China for about "joint first authors 60 years, and, in 2018, their role has expanded to include the formulation and evaluation of national cancer control National Cancer Center/ programmes and the care of patients with cancer. The purpose of this Review is to provide an overview of the key National Clinical Research Center for Carson /Cancer milestones in the development of cancer registration in China, the current status of registry coverage and quality, and Hespital, Chinese Academy of a description of the changing cancer profile in China from 1973 to 2015. This Review is a comprehensive and updated Medical Sciences and Peking review on the development of population-based cancer registries in China over a 60-year time span. We highlight Union Medical College, Brilling, some aspects of cancer control plans that illustrate how cancer registration data have become central to the China (Frof Wiles PhD. H Zong (ND, 8 Zhing MPH. identification of health priorities for China and provide a means to track progress in cancer control for the country. 5 Zhang #Ch L An #Ch

Introduction

Although technological development and the value of cancer control programmes. registries have led to increases in data quality and use over the past decades in high-income countries, increasing Key milestones in the development of cancer inequities in health resources and competing priorities registration in China have resulted in inadequate availability of high-quality. The first Chinese cancer registry was established in cancer data in many developing countries. The pace of Linzhou in 1959," when an oesophageal cancer survey was development for cancer registration has been much done in Taihang-an area with a high incidence of the

ElDen Phil, SWang Phil, burden in China, and the role of cancer registration in chieren perjorance Recolution, Issuel Cancer Registry Section, Division of

Services, National Carver Center, Tokyo, Japan (T Matsuda PhO); and Cancer Surveillance Section. International Agency for slower in developing countries than in developed disease." In 1963, Shanghai established the first urban Research on Cancer, Lyon,

GBI Newsfeed May 2021

China joins WHO's cancer research agency IARC

05/20/2021 China Policy / Regulatory Pharma & Biotech, Device & Diagnostics

China this week became a member of the International Agency for Research on Cancer (IARC), the World Health Organization's specialist cancer agency. The country is the 27th participating state in the IARC, which states its mission is to coordinate and conduct research into the causes of cancer, the mechanisms of carcinogenesis, and to develop strategies for cancer control.

The entry of China in the IARC means that the country can "shape global research priorities in cancer control and prevention" within the network, according to the press release. Tha IARC has long been active in China, collaborating on cancer research projects with local institutions, and training Chinese scientists at the agency's base in Lyon, France.

Objectives of the project

- Explore China cancer registry and assess cancer treated patient numbers in China by tumor and key city
- Combine with Market Sizing Study new patient / treatment / cancer treatment rates
- Target usage : commercial assessment Oncology Pharma industry
- Led with the guidance of senior epidemiologists from Cancer Foundation of China :
 - Incidence : confirmed only new cases
 - Calculation of nb Yearly nb of patients





Release used in initial project



Beijing January 21 2020, Carole Gabay meets with :

Xiao Nong Zou Deputy chief, Branch of Tobacco Control & Lung Cancer Control Cancer Foundation of China

And

Pr Ping Zhao, President, Cancer Foundation of China

Selection of cities entered from 2017 registry

		2	ranking of China cit	ies in Dosage Units	(Ma	arch 2016)
		3				
		4	city entered for can	cer registry data		
		5				
		6			28	Kunming
		7	Shanghai			Shijiazhuang
		8	Beijing		30	
		9	Guangzhou		31	Wuxi
		10	Chongqing	Fuzhou +	32	
		11	Fuxiaquan	Xiamen in Fujian	33	
		12	Chengdu	province	34	Harbin
		13	Tianjin		35	Nanchang
		14	Wuhan		36	Guiyang
		15	Hangzhou		37	Xuzhou
Some Major		16	Nanjing		38	Changchun
cities not		17	Changsha		39	Dalian
covered in		18	Pearl River Delta		40	Wulumuqi
covered in		19	Shenyang		41	Lanzhou
registry	→	20	Zhengzhou			
- ·		21	Suzhou			
		22	Wenzhou			
		23	Shenzhen			
		24	Xian			
		25	Jinan			
		26	Ningbo			
		27	Qingdao			

Entered cities included in Market Sizing Study providing rate of new patients / treated / cancer-drug treated

They represent **86%** of Oncology Drugs Sales in Hospitals (82% in volume source IQVIA CHPA)

13% of total China Population

17% of cancer patients (source registry)

88P	L
China	
Eastern China	
Middle China	
Western China	
•	

entered total China and regions used as proxy for non entered registries

Population of all Shi, Xian and Qu compared to registry coverage 2019 update : updated numbers entered

Desk research data

Wikipedia for 2010 census – integration of 2020 national census data

					I									1														
E	F	G	Н	1	J	К	L	М	N	0	Р	Q	R	S	Т	U	V	Y	Z	AA	AB	AC	AD	AE	AF	AG	AH	AI
Province	Pinyin no accents	Pinyin with accents	prefecture	mandarin	<u>Status</u>	Population 2000	Population 2010	Population 2017		Population 2020 census	<u>est 2016.</u> Population	covered by	rural areas covered by registry 2017		duplicate	Region 4 clusters + Tier I	Region 3 clusters	Population covered by registry 2019	rural areas covered by registry 2019	total population covered 2019	rejected 2019	new in 2019	rejected 2017	in book 2017	in book 2019	population covered growth	declining covered population	coverage rate 2019
Anhui	Bozhou City	Bózhōu Shì	Bozhou	亳州市	Prefecture	5,078,908	4,850,657	5,168,800	0	4,850,657	5,168,800			0	yes	East	Middle											-
Anhui	Chizhou City	Chízhōu Shì	Chizhou	池州市	Prefecture	1,389,469	1,402,518	1,449,300	0	1,402,518	1,449,300			0	yes	East	Middle											-
Anhui	Chuzhou City	Chúzhōu Shì	Chuzhou	滁州市	Prefecture	4,001,488	3,937,868	4,076,200	0	3,937,868	4,076,200			0	yes	East	Middle											-
Anhui	Fuyang City	Fùyáng Shì	Fuyang	阜阳市	Prefecture	8,003,963	7,599,913	8,092,600	0	7,599,913	8,092,600			0	yes	East	Middle	659,140		659,140					1			8%
Anhui	Hefei City	Héféi Shì	Hefei	合肥市	Prefecture	6,392,122	7,457,027	7,965,300	0	5,702,466	7,965,300	2,430,768		2,430,768	yes	East	Middle	2,454,656		2,454,656				1	1	1%		31%
Anhui	Huaibei City	Huáiběi Shì	Huaibei	淮北市	Prefecture	1,878,164	2,114,276	2,227,900	0	2,114,276	2,227,900			0	yes	East	Middle											-
Anhui	Huainan City	Huáinán Shì	Huainan	淮南市	Prefecture	3,153,218	3,342,012	3,487,000	0	2,333,896	3,487,000			0	yes	East	Middle											-
Anhui	Huangshan City	Huángshān Shì	Huangshan	黄山市	Prefecture	1,370,377	1,358,980	1,384,400	0	1,358,980	1,384,400			0	yes	East	Middle											-
Anhui	Liu'an City	Lù'ān Shì	Liu'an	六安市	Prefecture	4,842,084	4,603,585	4,800,300	0	5,611,701	4,800,300			0	yes	East	Middle											-
Anhui	Ma'anshan City	Mă'ānshān Shì	Ma'anshan	马鞍山市	Prefecture	2,193,546	2,202,899	2,301,600	0	1,366,302	2,301,600	638,060		638,060	yes	East	Middle	637,706		637,706				1	1	0%		28%
Anhui	Suzhou City	Sùzhōu Shì	Suzhou	宿州市	Prefecture	5,516,423	5,352,924	5,656,900	0	5,352,924	5,656,900			0	yes	East	Middle											-
Anhui	Tongling City	Tónglíng Shì	Tongling	铜陵市	Prefecture	1,442,667	1,562,670	1,608,000	0	723,958	1,608,000	448,736		448,736	yes	East	Middle	447,787		447,787				1	1	0%		28%
Anhui	Wuhu City	Wúhú Shì	Wuhu	芜湖市	Prefecture	3,367,502	3,545,067	3,696,200	0	2,263,123	3,696,200	1,478,663		1,478,663	yes	East	Middle	1,447,083		1,447,083				1	1	-2%	1	39%
Anhui	Xuancheng City	Xuānchéng Shì	Xuancheng	宣城市	Prefecture	2,659,639	2,532,938	2,613,800	0	2,532,938	2,613,800			0	yes	East	Middle											-
Beijing	Beijing City	Běijīng Shì	Beijing	北京市	Province-le	13,569,194	19,612,368	*****	0	19,612,368	21,707,000	8,289,660	4,959,016	13,248,676	yes	Beijing	East	8,452,233	5088031	13,540,264				1	1	2%		62%
Fujian	Fuzhou City	Fúzhōu Shì	Fuzhou	福州市	Prefecture	6,386,015	7,115,369	7,660,000	0	7,115,369	7,660,000			0	yes	South	East											-
Fujian	Longyan City	Lóngyán Shì	Longyan	龙岩市	Prefecture	2,684,310	2,559,545	2,640,000	0	2,559,545	2,640,000			0	yes	South	East											-
Fujian	Nanping City	Nánpíng Shì	Nanping	南平市	Prefecture	2,816,581	2,821,996	2,680,000	0	2,645,548	2,680,000			0	yes	South	East											-
Fuilan	Ningde City	Nínadá Shì	Ninade	中海市	Drefecture	2 991 258	2 778 508	2 900 000	0	2 821 996	2 900 000			n	VOC	South	Fact											-

Updated

coverage rate

All territories entered and population covered for all registries matched with the list

Entered from registry

																		N N										
E	F	G	Н	l I	J	K	L	М	N	0	Р	Q	R	S	Т	U	V	Y	Z	AA	AB	AC	AD	AE	AF	AG	AH	AI
Province	Pinyin no accents	Pinyin with accents	prefecture	mandarin	<u>Status</u>	Population. 2000	Population 2010	Population 2017		Population 2020 census	est 2016 Population	Population covered by c registry 2017 re	overed by		duplicate	Region 4 clusters + Tier I	Region 3 clusters	Population covered by registry 2019	rural areas covered by registry 2019	total population covered 2019	rejected 2019	new in 2019	rejected 2017	in book 2017	in book 2019	population covered growth	cousted	coverage rate 2019
Anhui	Bozhou City	Bózhōu Shì	Bozhou	亳州市	Prefecture	5,078,908	4,850,657	5,168,800	0	4,850,657	5,168,800			0	yes	East	Middle											-
Anhui	Chizhou City	Chízhōu Shì	Chizhou	池州市	Prefecture	1,389,469	1,402,518	1,449,300	0	1,402,518	1,449,300			0	yes	East	Middle											-
Anhui	Chuzhou City	Chúzhōu Shì	Chuzhou	滁州市	Prefecture	4,001,488	3,937,868	4,076,200	0	3,937,868	4,076,200			0	yes	East	Middle											-
Anhui	Fuyang City	Fùyáng Shì	Fuyang	阜阳市	Prefecture	8,003,963	7,599,913	8,092,600	0	7,599,913	8,092,600			0	yes	East	Middle	659,140		659,140					1			8%
Anhui	Hefei City	Héféi Shì	Hefei	合肥市	Prefecture	6,392,122	7,457,027	7,965,300	0	5,702,466	7,965,300	2,430,768		2,430,768	yes	East	Middle	2,454,656		2,454,656				1	1	1%		31%
Anhui	Huaibei City	Huáiběi Shì	Huaibei	淮北市	Prefecture	1,878,164	2,114,276	2,227,900	0	2,114,276	2,227,900			0	yes	East	Middle											-
Anhui	Huainan City	Huáinán Shì	Huainan	淮南市	Prefecture	3,153,218	3,342,012	3,487,000	0	2,333,896	3,487,000			0	yes	East	Middle											-
Anhui	Huangshan City	Huángshān Shì	Huangshan	黄山市	Prefecture	1,370,377	1,358,980	1,384,400	0	1,358,980	1,384,400			0	yes	East	Middle											-
Anhui	Liu'an City	Lù'ān Shì	Liu'an	六安市	Prefecture	4,842,084	4,603,585	4,800,300	0	5,611,701	4,800,300			0	yes	East	Middle											-
Anhui	Ma'anshan City	Mă'ānshān Shì	Ma'anshan	马鞍山市	Prefecture	2,193,546	2,202,899	2,301,600	0	1,366,302	2,301,600	638,060		638,060	yes	East	Middle	637,706		637,706				1	1	0%		28%
Anhui	Suzhou City	Sùzhōu Shì	Suzhou	宿州市	Prefecture	5,516,423	5,352,924	5,656,900	0	5,352,924	5,656,900			0	yes	East	Middle											-
Anhui	Tongling City	Tónglíng Shì	Tongling	铜陵市	Prefecture	1,442,667	1,562,670	1,608,000	0	723,958	1,608,000	448,736		448,736	yes	East	Middle	447,787		447,787				1	1	0%		28%
Anhui	Wuhu City	Wúhú Shì	Wuhu	芜湖市	Prefecture	3,367,502	3,545,067	3,696,200	0	2,263,123	3,696,200	1,478,663		1,478,663	yes	East	Middle	1,447,083		1,447,083				1	1	-2%	1	39%
Anhui	Xuancheng City	Xuānchéng Shì	Xuancheng	宣城市	Prefecture	2,659,639	2,532,938	2,613,800	0	2,532,938	2,613,800			0	yes	East	Middle											-
Beijing	Beijing City	Běijīng Shì	Beijing	北京市	Province-le	13,569,194	19,612,368	******	0	19,612,368	21,707,000	8,289,660	4,959,016	13,248,676	yes	Beijing	East	8,452,233	5088031	13,540,264				1	1	2%		62%
Fujian	Fuzhou City	Fúzhōu Shì	Fuzhou	福州市	Prefecture	6,386,015	7,115,369	7,660,000	0	7,115,369	7,660,000			0	yes	South	East											-
Fujian	Longyan City	Lóngyán Shì	Longyan	龙岩市	Prefecture	2,684,310	2,559,545	2,640,000	0	2,559,545	2,640,000			0	yes	South	East											-
Fujian	Nanping City	Nánpíng Shì	Nanping	南平市	Prefecture	2,816,581	2,821,996	2,680,000	0	2,645,548	2,680,000			0	yes	South	East											-
Fuilan	Ningde City	Nínadá Shì	Ninade	中海市	Drofocture	2 991 258	2 778 508	2 900 000	n	2 821 996	2 900 000			n	VAC	South	Fact											-

China cancer Registry 2019 vs 20)17 - change	s in territory	participation	and population	n registered		
<u>at Shi / Xian / Qu level</u>							
					_		
	nb of ter	ritories part	ticipating		Population regi		
				overall	at constant parti	cipating Shi /	Xian/ Qu
					nb of prefectures		
				population	with declining		minimum
				covered	population	maximum	change or
Mainland China Province	2017	2019	change	growth	covered	growth	decline
Beijing	2	2	0%	2.2%		2%	09
Tianjin	2	2	0%	2.7%		3%	09
Hebei	23	27	17%	10.9%	1	98%	-59
Shanxi	16	16	0%	0.4%	1	2%	-19
Inner Mongolia	13	10	31%	22.1%	2	3%	-219
Liaoning	15	15	0%	25.1%	3	1%	-29
Jilin	9	36	300%	77.6%	3	1%	-6%
Heilongjiang	9	11	22%	-6.9%	2	2%	-189
Shanghai	1	1	0%	-1.8%	1	2%	-29
Jiangsu	36	42	17%	2.8%	4	7%	-79
zhejiang	14	14	0%	1.9%	1	3%	-19
Anhui	23	25	9%	7.8%	2	9%	-29
Fujian	11	12	9%	8.2%	1	9%	-29
Jiangxi	11	12	27%	87.9%	1	2%	-69
Shandong	30	32	7%	3.1%	1	8%	-19
Henan	34	38	12%	19.9%	1	44%	-29
Hubei	13	17	31%	34.2%	3	3%	-69
Hunan	23	25	9%	13.9%	2	14%	-19
Guangdong	17	18	6%	21.1%	2	14%	09
Guangxi	11	24	118%	170.8%	1	5%	-269
Hainan	6	6	0%	29.1%	1	1%	-159
Chongqing	21	27	29%	251.5%	1	10%	-10/
Sichuan	21	61	205%	201.6%	6	25%	-269
Guizhou	20	17	89%	133.6%	1	42%	-20/
Yunnan	19	52	174%	43.0%	1	-42/0	-27
Tibet Autonomous Region	3	5	67%	-27.1%	1	0%	-279
Shaanxi	30	63	110%	30.5%	4	8%	-277
Gansu	15	15	0%	-0.4%	2	30%	-139
Qinghai	8	15	0%	17.8%	1	2%	-13/
Ningxia	9	9	0%	26.2%	2	25%	-49
Xinjiang	5	8	60%	-26.6%	2	23%	-47
Corps	2	3	50%	-20.076		21/0	
total participating registries	464	667	44%	28%			
total validated registries	338	486	44%	20/0			
% validation	73%	73%					
key data on all sites exc C44	1370	13/0					
incidence	818,415	1,101,897	35%	for an	alysis of incidence / gro	wth by proving	e. we
deaths	498,228	672,586	35%		o run the full project a		
deaths on incidence	496,226	61%	5576		of data		
acauls on incluence	01/0	0176					

Gansu : high growth of prefecture of Qingcheng, no change of territory definition

Comparison of 2017 and 2019 registries

List of diagnosis : unchanged

List of registries : increased by 44%, yet :

- Unchanged rate of drop off (participating registries that do not receive validation to be published in the book) of 27%
- Still 2 large cities not validated or participating : Nanjing & Zhengzhou

On key data :

Total incidence : +35%, to be analysed with incremental population covered added to the validated registries

Ratio of deaths / incidence unchanged





Structure of data entry file

		Data entry				Y		Calc	ulati	on ar	nd br	idginį	g				arket searc ta			
geography moin	Province region	tumor site 🚽	Site 🔽	Gender	incidence mo	orta	/early nb patier 👻	mortality rati	n	province prox	coverage rate 👻		rojected	Diagnosis of A	Diagnosis label Market sizin study		rate of treat	rate of cancer drug	projected treated patients	cancer drug
2 China	total CN	Lip, oral cavity, Pharynx but Naso	Lip	both sexes	465	118	862	13,69%		0.254521	0.254521	1,827	3,387	Head & neck of		54%	87%	82%	2,935	2,408
3 China	total CN	Lip, oral cavity, Pharynx but Naso	Tongue	both sexes	2,033	1,010	3,769			0.254521	0.254521	7,988	14,809	Head & neck of	thHeadNeck	54%	87%	82%	12,834	10,527
4 China	total CN	Lip, oral cavity, Pharynx but Naso	Mouth	both sexes	2,767		le.gabay: nption :Ye			0.254521	0.254521	10,871		Head & neck of	\\	54%	87%	82%	17,467	14,328
5 China	total CN	Lip, oral cavity, Pharynx but Naso	Salivary Gland	both sexes	1,687		tients = In			0.254521	0.254521	6,628		Head & neck of	icon with	54%	87%	82%	10,649	8,736
6 China	total CN	Lip, oral cavity, Pharynx but Naso	tonsil	both sexes	370		e of new pa			0.254521	0.254521	1,454	2,695	He Oncology M	larket	54%	87%	82%	2,336	1,916
7 China	total CN	Lip, oral cavity, Pharynx but Naso	Other Orophary	both sexes	597			n Market <mark>%</mark>		0.254521	0.254521	2,346	4,349	He Research s	urveys	54%	87%	82%	3,769	3,091
8 China	total CN	Nasopharynx	Nasopharynx	both sexes	9,685	5, Sizing	g study)	%		0.254521	0.254521	38,052	82,574	Na		46%	93%	90%	77,172	69,831
9 China		Lip, oral cavity, Pharynx but Naso	Hypopharynx	both sexes	1,379			%		0.254521	0.254521	5,418	10,045	He		54%	87%	82%	8,705	7,141
0.011	le e Love		et	1	507	100	4 4 6 7	20.05%		0.054504	0.054504	0.045	1 2 4 2			E 407	070/	000/	0.700	0.001

2019 data integration : we can analyse changes by registry 2019 vs 2017, and identify potential outliars

ICD-10	tumor site 🗸	Site	ICD-10	tumor site	Site
000	Lip, oral cavity, Pharynx but Nasc	Lip	C56	Ovary	Ovary
C01-C02	Lip, oral cavity, Pharynx but Naso	Tongue	C57	1.2352	Other Female Genital Organs
C03-C06	Lip, oral cavity, Pharynx but Naso		C58		Placenta
C07-C08	Lip, oral cavity, Pharynx but Naso		C60		Penis
C09	Lip, oral cavity, Pharynx but Nasc		C61	Prostate	Prostate
C10	Lip, oral cavity, Pharynx but Nasc		C62	Testis	Testis
C11	Nasopharynx	Nasopharynx	C63	bridgen of the second bad statement as	Other Male Genital Organs
C12-C13	Lip, oral cavity, Pharynx but Nasc		C64 C65	Kidney & unspecified Urinary or	Renal Pelvis
C12-C13	Lip, oral cavity, Pharynx but Nasc		C66		Ureter
C14 C15	11 11 1		C67	Bladder	Bladder
	Esophagus	Esophagus	C68		Other Urinary organs
C16	Stomach	Stomach	C69		Eve
C17		Small intestine	C70-C72	Brain, Central Nervous system	Brain, nervous system
C18	Colon, Rectum & Anus	Colon	C73	Thyroid Gland	Thyroid Gland
C19-C20	Colon, Rectum & Anus	rectum	C74	a statistica a second	Adrenal Gland
C21	Colon, Rectum & Anus	Anus	C75		Other Endocrine
C22	Liver	Liver	C81	Lymphoma	Hodgkins disease
C23-C24	gallbladder etc	gallbladder	C82-C85;C	SLymphoma	Non-Hodgkins Lymphoma
C25	pancreas	pancreas	C88		Immunoproliferative Disease
C30-C31	Lip, oral cavity, Pharynx but Nasc	Nose, sinuses, etc.	C90		Multiple Myeloma
C32	Larynx	Larynx	C91	Leukemia	Lymphoid Leukemia
C33-C34	Trachea, bronchus and lung	Trachea, bronchus and lung	C92-C94	Leukemia	Myeloid Leukemia
C37-C38	Other Thoracic Organs	Other Thoracic Organs	C95	Leukemia	Leukemia of unspecified cell type
C40-C41	Bone	Bone	0&U	all other sites & unspecified	Other and Unspecified
C43	Melanoma of skin	Melanoma of skin	all sum exclusion		all site sum C44 Other Malignant Neoplasms of skin
C44		Other Skin	all report		reported all sites
C45		Mesothelomia	all report		all sites except C44 reported
C46		Kaposi sarcoma	anreport		an store except on reported
C47-C49		Connective and Soft Tissue	i I		
C50	Breast	Breast		Compared the sum and	
C51	5.Cast	Vulva	fi l	reported total for sanit	У
C52		Vagina	ti l	check after each	
C52 C53	Cervix Uteri	Cervix Uteri		geography entry	
			-	Beographiy entry	
C54 C55	Uteris & unspecified Uteris & unspecified	Corpus Uteri Uterus unspecified	ť		

List of 61 diagnosis provided for China and regions

List of 25 diagnosis provided for Shi, Xian and Qu (97% of total incidence)

Lip, oral cavity, Pharynx bu	it Nasopharync
Nasopharynx	Important
Esophagus	<u>Important</u>
Stomach	Diagnosis missing
Colon, Rectum & Anus	Split of leukemia
Liver	•
gallbladder etc	and lymphomas
pancreas	Sarcomas
Larynx	
Trachea, bronchus and lun	_g Multiple myeloma
Other Thoracic Organs	
Bone	
Melanoma of skin	
Breast	
Cervix Uteri	
Uteris & unspecified	
Ovary	
Prostate	
Testis	
Kidney & unspecified Urin	ary organs
Bladder	
Brain, Central Nervous sys	tem
Thyroid Gland	
Lymphoma	
Leukemia	
all other sites & unspecifie	ed
all sites reported	
all sites reported nut C44	
all sites sum	dreom

Important Diagnosis missing : Acute vs chronic leukemias 2211 rows entered – 17 cities + 4 clusters for 25 or 60 diagnosis, male and female, incidence and mortality : total 4133

No change between 2017 and 2019 books

Applying the coverage rates by territory we can get a bottom up calculation of nb of living cases (Prevalence)

CHAR	•	\times	~	fx.	=IF(P797=0;L797;L	. <mark>797/P7</mark> 97)																
D	E		F		G	н	I	J	к	L	М	N	0	Р	Q	R	S	т	U	v	w	Х	Y
										Yearly nb	mortality	populatio	province	coverage	projected	projected	Diagnosis of	 Diagnosis label 	rate of	rate of	rate of	projected	projected
geography r	Province	e	region		tumor site	Site	Gender	incidence	morta	patiel 👻	catio	n	prov		incide -	nb Yearly	focus -	Market sizin-	nev:	treated	cancer	treated	cancer
1	×			× .	<u> </u>				*	patiel	ALI	cover	popul		inclue 🗸	patie	iocus 🗸	studv	patiei	patie	drug	patients	drug
797 Hangzhou	Zhejiang	Eas	st	gallb	bladder etc		Male	150	135	438	30.79%	0.747648	0	0.747648	201	P797)	rest of Hepa	intestine	34%	93%	90%	543	487
798 Hangzhou	Zhejiang	Eas	st	pano	creas		Male	387	421	813	51.78%	0.747648	0	0.747648	518	1,088	pancreas	pancreas	48%	50%	55%	543	299
799 Hangzhou	Zhejiang	Eas	st	Lary	nx		Male	134	51	338	15.08%	0.747648	0	0.747648	179	452	Head & neck	othHeadNeck	40%	87%	86%	395	340
800 Hangzhou	Zhejiang	Eas	st	Trac	hea, bronchus and lung		Male	3,005	2,785	5,736	48.56%	0.747648	0	0.747648	4,019	7,671	NSCLC	NSCLC	52%	96%	90%	7,368	6,652
801 Hangzhou	Zhejiang	Eas	st	Othe	er Thoracic Organs		Male	49	20	106	18.82%	0.747648	0	0.747648	66	142	lung other	Lungsmallcell	46%	83%	75%	5 118	89

With the 2019 book, we extend the data capture to all the registries

Scrap technology on pages of cancer Registry 2019 book

2017 book : 336 registries - 2019 book : 486 registries

Example of paper page from registry

18 CE	Table 6-3-26 Inc	_		RIE	Maie					ATL Fe	Sec. 2. 2		_	
570		10.0120 745.	HUE (%)	Mill Outline rests	REAR ADR WORL	Re Cuma		-	-	NE# Grude	NGR NGR	W.M.		KO 10
g il butterie				10103	(Util)	9-64	6-74	10005	na	1010	world (Inter)	0-84	0-74	
自然市场建计具有经	Lipilital Gent & Players but Novellation	1.10	1.00				maker							ALC: NO.
A-1112	Norrybutyree		/ A. S. A. COCCO.	0.00	0.00	0.00	0.00		1.88	1.1.85	2.83	8.28	125	00-RLCD 14
88	Orosphages	in	100	9.95	1.24	0.05	0.16		0.00	8.00	0.00	8.00	0.00	01
	Needb	19		17.20	3410	BAE	0.70	(W	1.85	5.89E	3,801	0.01	1.00	CH .
结查施现73	Colori Bierrari & Anna	- 10	1000	17.20	54.87	0.91	1.74	18	104	4.74	6.84	14:34	1.00	CI.
FR	Um.	39	12.01	Mart	18.25	1.40	1.87	12	5.66	11.48	10.08		3.44	09-31
DRANK	Gelbiation en:	100	0.00	0.00	0.00	0.00	4.00		1.00	1.95	1.00	0.10	61.54	422
98	Patrena	1.14	0.46	8.91	2.41	0.00	0.00	14	242	1.74	440	- Bat	442	625
B	Lann	- 14	1.81	3ml	TAT	432	8.82	- 12	842		11.50	BUT	0.07	Cit
和常产生,受了	Desites, Breakss and Ling	- 95	43,78	86.01	26.34	4.99	114		31.91	1110	17.14	2.82	111	428-424
其他時的設定	Other Tarracie Organa	1	0.66	0.93	0.912	0.00	823		000	1000	0.00	0.00	0.00	Cat-Cat
8	Born	12	0.91	1.81	1.73	0.52	8.17	1.4	20.62	0.000	18.17	0.00	1.11.19	C49-530
次扶扶的案框 ·	Molamona id Skie ::	11	0.40	0.91	0.89	0.00	8.09	- 0	0.00	0.00	800	0.00	0.00	1643
此時	Broast	- 21	0.40	0.01	0.81	0.06	0.00	43	36.47	00.04	49.75	5.62	4.21	(36
P108	Gersia Desi	1.1							+42	10.59	9.01	0.13	DER	633
学育体生于首联位不可	Lines & Unperiled	12	-	1.4	4	-		100	128	2.89	2.24	0.04	16.25	056-025
	Overy	1.00						11	2.04	11.55	8.87	9.51	3.79	136
ana i	Prostate	12	0.91	141	1.45	0,01	8.25	100	2					CH
11.	Tests	0	8.00	0.04	.0.00	0.00	11.00				1.3			00
大正就系统下用	Kalary & Doposited Lineary Organs	1 4	1.83	5.62	264	6.21	0.27	1.14	1.8.8					
and the second second	Malor.	10	4.57	115	TH	0.43	8.90	3	.1.20		1.17			
A REAL PROPERTY AND	Bran Central Nervous Servert	14	1.87	1.62	2.48	0.12	8.12	3	1.14					and a state of the
10.0	Through Clara?	1	0.68	0.90	0.55	UUT	10.0	10	50					
HC III		0	10.00	0.00	0.00	0.00	8.00	10	0.00					
	Linghama.	1	1.85	5.62	3.36	0.65	0.13	1	小市市	1 0.00				
	Londownin American	11.	5.00	9,95	8.06	0.46	8.66	11	410					
用当其指要性肿瘤	All Other Sites and Disspectivel	219	1085.042	198.29	10525	10.38	16.70	239	100.00	1.00				
前岸设备计	All Shee	218	100.00	106.90	16525	10.88	18.70	228	100.0	0 TPA.5	1.1864	1 313	a ila	0. MILLIGAN

List of prefectures to « scrap »

territory type	Province	Pinyin no	Riman.with, Ascenta (gradestars .	menilaria	Execution.	Energy and	Fidentiation 2012 action	countedby register
5h)	Hebel	Carigihou City	Cângzhôu Shi	Cangphou	治州市	1,04,062	2,584,890		906,57
sh)	Hebei	Dinhuangslad City	Cinhulogdão S	Qinhuangteo	秦皇岛市	2,907,085	1,00,000	1	710,67
shi	Hebei	Shiplazhuang City	Shiji ikshuling Sh	Shijlazhuang	石家庄市	10,612,788	6,073,500		1,016,550
shi .	Helionglang	Mudanjiang City	Müdänjiäng Shi	Mudenjiartg	社舟江市	2,796,722	2,799,723	+	148,025
shi	Henan	Anyting City	Anyong Shi	Anyong	卖阳市	6,072,000	\$,110,000		1,03,404
shi	Henan	Hebi City	Hebi Shi	Hebi	載量市	1953,244	1/520.000		534,834
5hi	Henan	Kaifeng City	Källfeng Shi	Kalferg	开封市	4,676,485	4.550,000		70,990
Shi	Henen	Luoyang City	Luchyang SN	Lucyang	溢阳市	6511.041	8,620,000		119,55
shi)	Henan	Sanmensia City	Sanminalà Shì	Sanmensia	主门城市	2,224,010	2,270,000	1	292,690
shi	Henan	Zherigzhou City	Zhèngthàu Shi	Zhengshoù	郑州市	8,822,089	6,080,000		2,654,065
shi	Hubel	Ershi Tujia and N	Enste Tujiazu M	Erishi Tujia and	思维土家族苗族自治州	3298,294	1,081000		829,823
Shi	Hubei	Vichang City	vichang Shi	Vichang	直腸市	4,0758,090	4,175,000	1	1396,435
Shi	lining54	Changehou City	Changzhou Shi	Changzhou -	常州市	4,8%,401	4,777,300		2,208,413
shi	Itangus	Hualan City	Huá/án Shi	Huatan	律安市	4,005662	4,988,000		546,686
shi	Dangiti	Liknyungang City	Liényúnging Sh	Lianyungeng	连云港市	4,333,485	4(36,400)		1004,471
shi	Hangsu	Nerrtong City	Nantóng Shi	Nantong	業通市	7,283,623	2,285,000		1.967,790
Shi	Jiangsu	Suzhoù City	Sighibu Shi	Buthou	苏州市	10.458,090	8,583,690		1,060.676
shi	liangsu	Wuxi City	WüstsN	Wuel	无端市	6,374,085	6,583,000		2,438,470
Shi	liangiu	Rushou City	Xuahdu Shi	Kuphter	徐州市	0.517.028	8.763.500		1000.024
shi	alle	Hilin City	Illin Shi	tites	吉林市	4.40.87	440357		1968,520
shi	lilin	Tonghue City	Tönghuà Shi	Tonghua	通化市	2,324,428	2324,400		243.958
shi	Lisoning	Anshan City	Anshian Shi	Anshan	教山市	1.845.004	2,585,000		100,060
shi	Lisoning	Benal City	Bênxî Shi	Behal	本属市	1708.578	1887,000		834.40
shi	Liaoning	Dandong City	Dandong Shi	Dandong	丹东市	2,444,097	2,595,680		704.085
Shi	Liaphing	Fuxin City	Púsin Shi	Fuxin	星新市	1898,008	1.780.000	1	842,450
shi	Lianning	Yingkou City	Yingkóu Shi	Yingkou	営口市	2 428 534	2,409,000		445,530
shi	Inner Mongol	Chifeng City	Chiffing Shi	Chifeng	去維市	4.54(2)()	6.256,0000		1229.045
shi	Ningsia	Guyuan City	Gùyuán Shi	Guyuan)的使击	1216.000	LINGT		123,688
Shi	Ningxia	Vinchuan City	Vinchuân Shi	Tinchuan	機用市	1950.000	2,225,781		1,832,885
shi	Qinghai	Kining City	Xining Shi	Xining	西宁市	1,208,798	2,595,000		343,595
Shi	Shandong	Qingdap City	Gingdão Shi	Dingdao	書島市	0.78.007	8,290,500		1744,082
shi	Shandong	Yantai City	Vantal Shi	Yantai	编绘击	9,968,982	7,089,408		1000,530
shi	Shansi	Yangguan City	Yangquan Shi	Yangquan	記象市	134.582	1400.010		707.54
shi	Tibel Autonon	A CONTRACTOR OF A CONTRACTOR A CONTR	Liksk Shi [Lhase	and the second sec	拉萨市	\$58,423			200.450
Shi	Zhejiong	Jipxing City	Sidwing Shi	liaxing	慶兴市	4.500/87	4,585,000	1	\$28,725
xian Gu	Anhui	Changfeng	Hefei	Anhui	County	629,535	-	625525	TOUNS
Kian Qu	Anhui	feidang	mefei	Anhui	County	661360		NUNE	1063.080
Kian Qu	Anhui	Petal	ristel	Annui	County	458.095		150.005	796,000
Kian Gu	Anhui	Luiteng	tiefei	Anhui	County	\$12,950		172.058	104.904
Xian Qu	Anhul	Cheohu	Nefei	Anhui	City	258,780		716,718	04.21
Xian Gu	Anhui	Wuhe	Benghu	Anhui	County	621.973		623913	863,581
Kian Chi	Anhui	Dingyuan	Chushou	Anhui	County	779.04		176.114	903.082
	Anhui	Tianchang	Chushou	Anhui	City	\$22,732		802.702	602.040

A complimentary contribution from Healthcare Strategic consulting firm L.E.K.



Replace with "scrapped" actual data for registry data instead of regional proxy

Eastern China Middle China Western China

Scrap technology to capture all the territories in the registry

between <			Appendiz Ta	dile 3-3 incidenc		of cance	rin Tianjin Sł	4,2016								
BRUE Notange BRUE Notange		and the second se			E S Male	-				10.00	241	emale		- Course	- Interior	
Bindom Interval <		BUT 9462	南京歌 No.cases	相信Fireq/st	1.MeV10000	ASR	and the local division in which the real division in the local div	Contraction of the Party Name			Crude	ASR	In case of the local division of the local d	and the second second second		
addNuclearing56667000 <t< td=""><td>Uff Insidence</td><td></td><td></td><td></td><td>- 01</td><td></td><td>0 0 04</td><td>0.14</td><td></td><td></td><td>Column.</td><td></td><td></td><td></td><td></td><td></td></t<>	Uff Insidence				- 01		0 0 04	0.14			Column.					
TExpand control <td>三部時代(決力条項表)</td> <td>Oral cavity & pharges ess na sopharges</td> <td>367</td> <td>154</td> <td>6.38</td> <td>325</td> <td>0.23</td> <td>0.37</td> <td>102</td> <td>0.69</td> <td>3.95</td> <td>1.96</td> <td>0.12</td> <td>0.20</td> <td>C09-10,C12-14</td> <td></td>	三部時代(決力条項表)	Oral cavity & pharges ess na sopharges	367	154	6.38	325	0.23	0.37	102	0.69	3.95	1.96	0.12	0.20	C09-10,C12-14	
SomainSoma	44	Nasophayes	51	0.47	t.95	123	0.08	0.12	16	0.14	0.68	8.21	0.02	0.04	Ctt	
LatColon wantsMode <td>T.</td> <td>Esophagos</td> <td>265</td> <td>2.45</td> <td>10.14</td> <td>4.53</td> <td>0.28</td> <td>0.55</td> <td>73</td> <td>8.64</td> <td>2.75</td> <td>0.91</td> <td>0.02</td> <td>0.10</td> <td>CR</td> <td></td>	T.	Esophagos	265	2.45	10.14	4.53	0.28	0.55	73	8.64	2.75	0.91	0.02	0.10	CR	
betUnrBetB	t i i i i i i i i i i i i i i i i i i i	Stomach	872	8.06	25.96	16.50	0.77	1.00	401	1.50	15.03	8.00	0.39	0.77	CIE	
BBLACONLOWERC1<	# # # # # # # # # # # # # # # # # # #	Colon, rectam & anas	103	10.19	42.20	13.39	100	2.32	884	7.72	33.25	14.16	0.74	167	C18-21	
BitPenneanDio<	i de	Liver	885	8.16	33.86	16.30	1.19	1.94	405	3.53	15.29	6.36	0.52	0.74	C22	
BitPenneanDio<	現立スセ	Galbladder etc.	231	2.13	0.04	3.77	0.20	0.42	261	2.28	9.95	3.00	0.16	0.45	C23-24	
T.T. P. T. No. Anomale i king300300300500500500700 <th< td=""><td>18</td><td>Panciess</td><td>283</td><td>3.54</td><td>14.65</td><td>6.86</td><td>0.40</td><td>0.82</td><td>293</td><td>2.58</td><td>15.05</td><td>4.51</td><td>0.19</td><td>0.57</td><td>C25</td><td></td></th<>	18	Panciess	283	3.54	14.65	6.86	0.40	0.82	293	2.58	15.05	4.51	0.19	0.57	C25	
Perform400.441.141.170.100.077.70.234.000.000.060.070.70.100.000.	 Second second sec	Largex	182	168	6.96	3.31	0.25	0.41	18	0.16	0.68	0.39	0.01	0.04	C32	
BoseDotDifDifDifDifDifDifDifDifDifDifDifDifDifBittattattatDirac <t< td=""><td>¥.2.7.¥. II</td><td>Trackea, bronchur & king</td><td>3058</td><td>28.25</td><td>16.33</td><td>51.76</td><td>2.52</td><td>6.55</td><td>1979</td><td>17,26</td><td>74.53</td><td>29.07</td><td>110</td><td>3.22</td><td>C33-34</td><td></td></t<>	¥.2.7.¥. II	Trackea, bronchur & king	3058	28.25	16.33	51.76	2.52	6.55	1979	17,26	74.53	29.07	110	3.22	C33-34	
Bit	他的我把算算	Other thoracic organa	40	0.44	184	1.17	0.08	0.12	37	0.32	1.40	0.98	30.0	0.11	C37-38	
Beam UP BX 0.05 4.20 4.10 1.20 4.10 1.20 4.10 1.20 4.10 1.20 4.10 1.20 4.10 1.2		Bone	73	0.67	2.79	194	0.12	0.17	71	9.62	2.68	168	0.00	0.16	C40-41	
2 Conversion 420 0.00 0.00 0.00 0.00 0.00 A Deag 270 230 0.00 770 0.80 0.00 770 0.80 0.00 770 0.80 0.00 0.00 770 0.80 0.00 0.00 770 0.80 0.00 </td <td>防犯果危累痛</td> <td>Melanoma ol skin</td> <td>24</td> <td>0.22</td> <td>0.92</td> <td>8.45</td> <td>0.00</td> <td>0.04</td> <td>. 24</td> <td>0.21</td> <td>9.91</td> <td>0.60</td> <td>0.00</td> <td>0.06</td> <td>C43</td> <td></td>	防犯果危累痛	Melanoma ol skin	24	0.22	0.92	8.45	0.00	0.04	. 24	0.21	9.91	0.60	0.00	0.06	C43	
Start Unexp <th< td=""><td>維</td><td>Breast</td><td>12</td><td>0.16</td><td>0.65</td><td>0.29</td><td>0.52</td><td>0.04</td><td>2190</td><td>19.10</td><td>82.90</td><td>46.09</td><td>386</td><td>523</td><td>C50</td><td></td></th<>	維	Breast	12	0.16	0.65	0.29	0.52	0.04	2190	19.10	82.90	46.09	386	523	C50	
A Design 70 70 70 70 80 70 80 70 80 70	#3	Cervicuteri	-	÷:	-	-		**	423	3.69	15.96	10.07	0.89	0.59	C53	
A Dorsy </td <td>查祥及子童制度不能</td> <td>Uterus & unspecified</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td></td> <td>-</td> <td>431</td> <td>3.76</td> <td>16.28</td> <td>8.43</td> <td>0.73</td> <td>0.97</td> <td>C54-55</td> <td></td>	查祥及子童制度不能	Uterus & unspecified	-	-	-	-		-	431	3.76	16.28	8.43	0.73	0.97	C54-55	
Photox Photox Physical Phys			-	-	-	-	-	-								
chTripHHH <td></td> <td></td> <td>451</td> <td>4.17</td> <td>17.25</td> <td>6.95</td> <td>0.18</td> <td>0.82</td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>			451	4.17	17.25	6.95	0.18	0.82		-						
Signification Signific									-	-		-	-			
Haden State State <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>264</td><td>2.30</td><td>3.96</td><td>4.07</td><td>0.30</td><td>0.50</td><td></td><td></td></th<>									264	2.30	3.96	4.07	0.30	0.50		
n # ### Disk tonolog sigtem 149 2.20 9.01 5.90 4.90 107<				4.72								2.29		0.24		
世態 世態 日本 <b< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></b<>																
Eff Lympions 554 209 127 6.89 6.44 0.01 223 2.47 0.09 5.40 0.22 0.01 0.23 2.47 0.09 5.40 0.22 0.01 0.23 0.23 0.24 0.02 0.01																
Δμ Lobertia 419 309 19.72 19.14 102 336 2.30 10.69 10.77 19.15 0.19 0.197 <td></td>																
102.25 103 442 103 314 105 100 447 418 172 0.18 0.18 A.0 102.25 1030 444 155 1030 492.3 201.4 1050 201.5 201.6 201.6 1000 402.8 201.6 1000 402.8 201.6 1000 402.8 201.6 1000 402.8 201.6 1000 402.8 201.6 1000 402.8 201.6 1000 402.8 201.6 1000 402.8 201.6 1000 402.8 400 000 0.00		DOT MANAGES														
PRECENT Adama 9025 9020 44.44 9043 155 23.42 1069 90.00 423.02 23.14 16.4 34.0 Defende HELEMPLE Adama 607.44 99.55 410.4 99.56 42.94.7 29.956 43.95 D21.95 D01.95 D21.95 D21.95 </td <td></td>																
THE Control North 99:25 4104 99:35 1150 22:25 1190 99:35 42:47 219:96 No.91 21:35 C001-98 ees. C44 EXENDER (10) A sees by bytegeneen namesphage 194 156 3.99 104 0.05 0.05 0.06 0.99 0.99 0.04 0.07 0.00 0.05 0.01 0.05 0.01 0.05 0.01 0.05 0.01 0.05 0.01 0.05 0.01 0.05 0.01 0.05 0.01 0.05 0.01 0.05 0.01 0.05 0.01 0.05 0.01 0.05 0.01 0.05 0.01 0.01 0.05 0.01 0.05 0.01 0.05 0.01 0.03 0.05 0.01 0.03 0.05 0.01 0.03 0.05 0.01 0.03 0.05 0.05 0.01 0.03 0.05 0.05 0.01 0.03 0.05 0.01 0.04 0.05 0.01 0.04 0.05 0.05 0.												221.24				_
Including Including <thincluding< th=""> <thincluding< th=""> <thi< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></thi<></thincluding<></thincluding<>																
Bit		10 2112 20 011	101111		411.94	100.00	in any		110000	10.00	Taro Tr	and the		80.99		
Nation Nation 35 0.42 1.1 0.05 0.05 0.02 0.02 0.02 0.02 0.02 0.01 0.02 0.01 0.02 0.01 0.02 0.01 <		Ord such h shunty are nanothenes	174	165	2.98	104	0.7	0.22	44	0.60	109	0.00	0.04	0.67	000.10 012.54	
Exophages 267 2.04 9.21 4.25 0.50 45 1.00 4.71 0.02 0.04 C15 Bornwin 550 6.54 22.03 3.54 0.40 113 2.78 5.20 3.18 0.39 0.39 0.35 C16 BE Lee 709 16.21 2.74 10.40 0.38 118 447 5.85 5.85 117 4.38 0.77 0.48 0.23 0.66 0.23 110 3.75 7.77 2.53 0.66 0.62 C22. 116 117 2.66 0.77 7.7 7.80 0.66 0.75 117 0.38 0.66 0.66 0.77 7.7 2.78 0.66 0.62 C22. 117 117 12.00 0.16 0.66 0.66 117 0.34 0.66 0.62 C32 117 12.00 0.14 117 2.00 0.16 0.16 0.16 0.16 0.16 0.16																
Itemach Stornach																
空気() Color, ventum b anus 651 6.37 2.4 m 0.20 0.38 119 647 8.80 5.66 5.94 0.23 0.55 CEN-21 B Liver 709 10.21 27.9 12.45 0.77 6.43 0.77 0.44 C.22 B Calsbadderett 171 2.56 6.01 0.33 100 3.75 7.07 2.59 0.64 0.23 0.03 0.64 0.59 7.77 2.59 0.64 0.59 0.03 0.64 0.59 0.03 0.64 0.59 0.03 0.64 0.64 0.69 0.69 0.69 0.69 0.69 0.69 0.69 0.69 0.69 0.69 0.60 0.62 C.32 C.32 Largen Trackes, bronclust is king 247 10.65 0.65 0.76 0.76 0.49 0.49 0.40 0.60 0.62 C.32 C.32 Light State Diver functor strabin 41 0.62																
Live 700 100 100 100 100 100 100 100 100 100	*85C													and the second second		
法法の合い Galibladier sta. 178 2.56 6.01 2.06 0.12 0.32 150 3.75 7.77 2.93 0.68 0.23 C23-24 188 Panesa 223 4.68 12.88 5.55 0.31 0.64 2.00 6.14 9.81 9.37 0.13 0.46 C23-24 188 Days 74 167 2.30 0.56 0.57 17 0.34 0.44 0.88 0.52 0.21 C23-24 17.57.97 Trashea, boondwar 6 king 2.471 35.85 94.73 36.22 0.44 0.85 0.30 0.32 0.46 0.35 0.25 0.41 0.65 C32 2.21 C23-34 Mathematic plan 14 0.33 0.52 0.41 0.41 0.42 0.45 0.49 0.25 0.41 0.43 0.52 C43 Mathematic plan 14 0.33 0.51 0.52 0.44 0.40 0.49 0.45 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>																
日本のの名広 日本のの名広 日本のの名広 日本のの名広 日本のの名広 日本のの名広 日本のの名 日本の名		0.552					and the second second									
Larges 74 147 2.83 123 0.05 0.75 17 0.34 0.64 0.89 0.60 0.62 C.32 T_C_T_H Taskes, bronchar h king 2470 35.85 94.73 30.73 162 4.76 107 33.00 63.04 0.85 0.24 0.05 0.73-34 Utry RegR Diver broacci organs 23 0.03 0.82 0.04 0.00 36 0.56 0.24 0.04 0.05 C13-34 Bitlinitian Ha 0.02 0.55 0.02 0.04 0.00 36 0.56 0.17 0.10 0.43 0.62 0.65 C40.41 Bitlinitian Ha 0.03 0.57 0.01 0.01 0.01 4.05 0.56 0.55 0.56 0.55 0.55 0.55 C40.41 Bitlinitian Processon Processon Processon Processon Processon Processon Processon Processon Processon Procestan																-
T.S.T.W. If Trackes, boonders is larg 2478 91.73 98.75 91.73 98.75 98.75 97.75 91.02 4.78 1877 32.00 63.04 0.55 2.21 C23.04 HattingBig Deter throase organs 2.3 0.33 0.88 0.62 0.04 0.05 10 0.28 0.49 0.04 0.05 0.15 0.05 0.01 0.05 0.05 0.01 0.05 0.05 0.01 0.05 0.05 0.04 0.05 0.05 0.01 0.05 0.05 0.01 0.05 0.05 0.01 0.05 0.05 0.01 0.05 0.05 0.01 0.05 <th0.05< th=""> <th0.05< th=""> <th0.05< td="" th<=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th0.05<></th0.05<></th0.05<>																
日本目的電音 Other throacide organs 22 0.23 0.88 0.62 0.04 0.05 13 0.26 0.49 0.01 0.63 C27-38 Bore Sore 43 0.62 155 0.92 0.04 0.01 36 0.59 110 0.43 0.02 0.05 C40.41 Bir Mith T Melanoma ci shin 14 0.03 0.57 0.00 0.01 4.06 0.05 0.01 0.02 0.48 0.01 0.02 0.43 0.56 0.01 0.02 0.43 0.56 0.01 0.02 0.43 0.56 0.01 0.02 0.43 0.56 0.01																
Bone 43 0.62 1.85 0.82 0.04 0.10 38 0.78 113 0.43 0.62 0.65 D40.41 Mithenmard Isin 14 0.20 0.54 6.25 0.00 0.00 0.24 0.45 0.81 0.01 0.62 0.45 0.81 0.01 0.62 0.45 0.81 0.01 0.62 0.42 0.45 0.81 0.01 0.62 0.45 0.81 0.02 0.62 0.43 0.82 0.43 0.62 0.44 0.62 0.45 0.83 0.62 0.45 0.41 Max Deve Canderoni - - - - - 101 139 231 248 0.42 0.53 0.53 Max Deve -		and the second se														
2012年ままる 語言																
日本att 「「日本 日本 一 日本 一 日本 日本 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>																
								7.77	1.788							
主流之子を副して対象 Unexa & numpediated - - - - - - - 10 2.32 4.45 1.86 8.8 0.22 C54-65 A Dowy -								0.01								
● Deep - - - - - - - 233 454 0.68 4.07 0.26 0.48 CS6 万勝 Prostare 249 359 957 3.00 0.02 0.25 - - - - - - C61 15. Tetls 4 0.06 0.07 3.00 0.02 0.25 - - - - C61 25/25/25/27 Nidreys burgestilledustragroupset 210 3.07 8.55 3.56 0.18 0.42 344 1.06 0.55 1.41 0.46 0.44 C64-46.64 166 Baldee 209 3.06 0.06 0.06 7.9 1.38 2.44 0.71 0.01 0.44 C64-46.64 168 Baldee 209 3.01 0.02 0.06 0.06 0.07 7.93 2.44 0.71 0.01 0.44 C74-46.64 0.73 1.91 8.61<	The first of the second s					-			and the second second							
Prostate 249 359 9.57 3.20 0.02 0.25 - - - - - - C61 15. Testis 4 0.06 0.07 0.02 0.01 - </td <td></td> <td></td> <td>-</td> <td>Π.</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>			-	Π.	-	-	-	-								
Pretis 4 0.05 0.15 0.00 0.01 - CRE CRE			-	0.00	0.52			4.75	230	4.54	0.58	4.00		0.48		
22年登場任予告 Notes 5 unspectified latitizang organs 213 307 8.55 356 0.18 0.42 94 106 355 141 0.66 0.14 C64-66,68 日本のにいいいいいいいいいいいいいいいいいいいいいいいいいいいいいいいいいいいい									-	- 40	-	-				
Biadder 209 3.01 8.08 3.05 6.06 0.30 78 1.38 2.44 8.71 0.01 0.64 D67 Intellistic Brain, nervous system 197 1.37 5.24 2.84 0.15 0.25 118 2.44 8.71 0.01 0.64 D67 Intellistic Brain, nervous system 197 1.37 5.24 2.94 0.15 0.28 118 2.35 4.48 0.00 0.03 0.20 CF07 D203.004243 VIB Typesid 16 0.23 0.61 0.20 0.04 4.48 0.00 0.00 0.67 CF3 Ellistic Lymphoma 214 3.08 6.99 3.82 0.21 0.43 M0 2.77 5.28 2.24 0.00 0.28 C58.68, 89, 90, 96 Ammonia Ledwortia Ledwortia 198 2.68 7.92 3.43 0.17 0.37 191 2.58 5.78 2.90 0.			1.7		and the second second					-				-		
時価単価 Drah. nervous system 137 5.24 2.04 0.15 0.28 113 2.25 4.49 2.09 0.10 0.23 C70-72_D12-33_D12-43 状態 Theyoid 16 0.23 6.05 6.05 6.04 4.8 0.79 151 6.01 0.00 0.67 C70-72_D12-33_D12-43 活動 Days 2.44 3.08 8.09 5.32 0.01 4.48 0.79 151 6.01 0.00 0.67 C70-72_D12-33_D12-43 生活 Laphonia 2.44 3.08 8.09 3.82 0.21 0.43 M0 2.77 5.28 2.24 0.00 0.00 2.05 C555.66, 56, 56, 56 血素 Ledentia Ledentia 196 2.88 7.92 2.44 0.17 0.37 191 2.86 7.78 2.39 0.14 0.28 C514.56, 56, 56, 56, 56 出た Charma Ledentia Data Data Data Data Data Data Da																
代册 Tagnol N 0.23 0.61 0.3 0.62 0.64 40 0.75 131 8.61 0.03 0.67 C73 医子 141 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5																
三番 Lynghoma 214 203 8:19 282 0.21 0.43 M0 2.77 5.28 2.24 0.10 0.25 C85.86,88,96,96 血母 Ledennia Ledennia 198 2.68 7.72 2.43 0.17 0.37 191 2.58 5.78 2.90 0.14 0.25 C31-35(2)647 型法工业型准備 Other and unspectived 227 3.27 8.68 4.00 0.20 0.43 193 2.31 7.28 2.81 0.14 0.27 A.D 常に出来 Alphana 4.00 0.26 C31-35(2)647						and the second second										
血液 Ledentia 196 2.68 7.12 2.43 0.17 0.37 151 2.38 5.78 2.90 0.14 0.28 C3135C045.47 地況高生世報価値 227 3.27 0.68 4.00 0.20 0.43 153 3.01 7.28 2.81 0.14 0.27 A_D 常知公士世報任 Allstes 6345 100.00 285.74 114.82 5.21 13.18 5943 100.00 19102 73.54 3.04 7.78 C06.36																_
변見其世際新聞 Other and unspecified 227 3.27 8.68 4.08 8.20 0.43 193 3.01 7.28 2.81 0.14 0.27 A_D 常知公士计 Allokes 6345 100.00 285.74 114.62 5.21 13.18 5943 100.00 19102 73.54 3.04 7.78 C08-36																
Ternica## Allohea 6946 000.00 265.74 114.62 5.21 13.06 5063 100.00 19102 73.64 1.04 7.76 C06-96																
Telefizie-atte All sized but CA4 6927 99.73 265.01 194.29 5.20 13.16 5048 99.70 190.46 73.48 3.04 7.77 C00.96 eeu C44																
	博士证单行支持	All skes but C44	6927	99.73	295.01	114.39	5.20	12.16	5046	99.70	190,46	73,48	3.04	7.77	C09-95 eeo C44	

 486 tabs like these captured on Excel with OCS technology

100.				各代常计层景											
486 ta	bs on Excel	Appe	可表3-11g nds Table 3-1kc	まき2016年基(idence and mo			g SHI,2016								
-				#isMale						文集	Ferriale				
	NGC SAva	南京街 No.sases	TERE Freq Pr	변후 Crude Later100000	世紀年 ASR world/1000	#HB Cu	m.Plateftc	· 南市街 No.cazes	明成 Fresht	변호 Crude tate/10000	표면표 ASR world/1000		um.Plateits	ICD10	
				1	.00*	0164	0-74		100.00	0.4	00.4	0*64	0*74		
型用 Insidence		2223	1.052	00.25					2250	L.				1	
□括約宿後(除り鼻宿寮)	Or all cavity & pharyns esc nasopharyne	258	162	6.10	2,15	0.23	0.37	161	0.97	2.01	192	0.11	0.21	C00-10,C12-14	
AGE	Nacopharges	46	0.29	1.09	8,61	0.04	0.06	22	0.13	0.52	0.35	0.03	0.03	CII	- A
**	Esophagus	510	3.26	12.25	5.35	0.33	0.67	110	0.71	2.79	0.07	0.02	0.07	CIS	i chi
•	Stomach	1124	7.07	26.57	91.84	8.62	140	677	3.43	13.68	6.23	0.07	0.78	C16	2 北东市 1
##850	Colon, rectum & anus	2358	14.63	55.75	25.51	140	313	1806	10.94	42.77	17.57	0.92	2.03	C18-21	 1.11年代 4.11年代
养護	Liver	1017	6.40	24.04	11.05	0.05	1.07	444	2.69	10.57	4.19	0.17	0.47	C22	1 1.98
经要交关地 油油	Galbladder etc. Pancreat	331 525	2.68	7.83	3.24 5.34	0.15	0.39	297	1.98	7.80	2.53	0.10	0.28	C23-24 C25	※ 北京市 》 》 北京市 》
4	Largna	156	0.98	2.69	1.80	0.26	0.05	10	0.12	0.45	0.17	0.00	0.45	C12	4 北京市 1 9 北京市 1
**************************************	Tractwabronchus & king	3609	22.70	85.33	37.94	183	4.82	2504	15.16	58.30	25.05	1.08	3.00	C33-34	10 此标件 6
其他的物性器官	Other thoracic organa	67	0.42	1.50	0.83	0.06	0.09	42	0.25	0.99	0.52	0.03	0.06	C37-38	11 北座市 H 12 北座市 H
	Bone	57	0.36	1.25	1.32	0.08	0.10	37	0.22	0.88	0.65	0.02	0.06	C40-41	12 北东市 6
皮肤的果色素瘤	Melanoma of skin	24	0.15	0.57	0.01	0.01	0.04	28	0.16	0.62	0.32	0.02	0.00	C43	14 北京市 (15 北京市 1
2.8	Breast	27	0.17	0.84	0.33	0.02	0.04	301	19.99	78.17	45.73	3.60	5.04	C50	16 北东市 1
≑ #31	Cervis uteri	M	ale i	nci	do	nco	·	389	2.36	9,21	5.93	0.50	0.61	C53	17 北京市 1
71 437 1 6279	Uterus & unspecified	IVI			de	nce	120	829	5.01	19.61	10.88	0.90	125	C54-55	10 北原市 1
S.A.	Ovary	-	(÷	-	-	~	-	541	3.28	12.81	7.49	0.54	0.04	C56	20 北岸市 10
87/18	Prostate	1100	6.97	28.29	10.95	0.32	1,45	IFe	em	ale	-	-	-	CEI	22 北京市 1 23 北京市 6
■ 九.	Testis	36	0.23	0.85	0.79	0.06	0.06	1.0		ure	-	-	-	C62	24 北京市 1
兼政业常具结不相	Kidney & unspecified urinary organa	862	5.42	20.38	10.72	0.71	1.28	586	3.43	13.40	6.10	0.33	0.74	C64-66,68	25 北座市 H 26 北座市 H
群性	Bladder	g17	5.14	19,32	8.08	0.36	0.95	1 H L	CIC	ien	CE	0.11	0.30	C67	27 北东市 1
我、神皇家族	Brain, nervous system	386	2.43	8.13	6.96	0.41	0.57	514	3.11	12.17	8.07	0.59	8,80	30.72. D32-33, D42-41	20 北东市 6
₹itä	Thyroid	018	6.15	19.34	14.70	120	1,28	2085	\$2,63	45.30	36,95	3.06	3.35	C73	IN HART I
82 9	Lymphoma	562	3,47	13.05	6.46	0.34	0.76	#40	2.66	10.42	5.00	0.00	0,58	C81-66,88,90,96	11 北田市 1
525 7827-888	Leukemis	453	2.85	10.71	6.75	0.06	0.62	321	1.94	7.80	5.02	0.27	0.43	C91-95,D45-47	11 北京市 1
不错说真性导情拼響 所有部位会计	Other and unspecified All sites	15896	6.70	17.68	9.80	0.50	0.98	746	4.52	17.67	8.56 206.61	0.48	0.09	A_0 C00-16	14 北原告 7 15 北原告 1
用者的立法外发统	All sites but C44	10079	Here a	910.0-2	106.04	W.ET	6160	69 George	100.00	39108	206.01	HANG.	\$5.27	C00-96 esc.C44	26 (L978) 5
RE Monality			S320				-0.00	-						Con the line of the	37 北京市 6 38 北京市 6
25%26(後方美信音)	Oral cavity & pharges ess nasopharges	172	167	4.07	1.73	0.11	0.18	73	1.01	1.73	0.88	0.01	0.07	C00-10,C12-14	29 北京市 H 40 北东市 H
808	Nasopharges	68	0.64	1.56	0.80	0.05	0.09	22	0.30	0.52	0.22	0.02	0.02	CH	41 北市市 6
**	Exophagus	470	4.56	11.11	4.50	0.26	0.50	129	1.77	3.83	0.92	0.01	0.08	C15	42 北东市 + 43 北东市 1
	Stomach	846	8.21	20.00	7.49	0.31	0.70	392	5.41	9.29	3,47	0.16	0.35	CIE	AL ILSE I
#重發程()	Colon, restum 6: anus	1980	11.45	27.90	10.37	0.41	1.09	857	11.84	20.30	6.58	0.24	0.62	C18-21	45 注意书 1
fill.	Liver	807	9.09	22.15	10:37	0.67	123	400	5.57	3,54	3.46	0.12	0.37	622	47 北京市 1
体展及其性	Galibladder etc.	313	2.04	7,40	2.95	0.94	0.33	290	3.97	6.83	2.33	0.09	0.27	C23-24	4日、北京市 1
AB	Pancreas	468	4.54	11.06	4.48	0.23	0.49	642	6.10	10.47	3.86	8.6	0.45	C25	50 北田市 1 51 北田市 6
e	Larges	91	0.89	2.15	0.87	0.04	0.11	15	0.21	0.36	0.11	0.00	0.02	C32	验 北座市 1
18,218. #	Trachea, bronchus & lung	0000	29.41	71.64	28.66	1.0	3.43	1707	27.59	40.42	13.54	0.47	140	C33-34	50 北京市 1 54 北京市 1
本他们和自己意 •	Other thoracic organs	43	0.42	1.02	0.51	0.03	0.05		0.29	0.50	0.22	0.01	0.03	C37-38	55 北非市 4
* 2001年11月1日	Bone Melanoma ol skin	25	0.34	0.83	0.41	0.02	0.03	34 20	0.47	0.61	0.46	0.02	0.05	C40-41 C43	36 北京市 1 12 北京市 1
2.000#127@ 2.8	Eleast	7	0.21	0.12	0.02	0.00	0.03	29 792	0.29	18.76	0.19	0.01	0.03	C43 C59	
710 710	Cervis uter:				the	0,00		152			104	0.52	0.33	C53	
7842788078	Uterus & unspecified	IVI	are	dea	cris		-	150	Ene	ema	ale	0.10	0.19	C54-55	
FA	Ovary	2	1	1	-	-	1	319	4.41	7.55	3.61	0.26	0.39	C56	
E7(8	Prostale	518	5.03	12.25	3.36	0.04	0.24			eat		-		CEL	
81.	Testis	6	0.05	0.12	0.05	0.00	0.01	-	ų	ται	112	-		C62	
*248.8874	Kidney & unspecified urinary organiz	190	2.72	6.62	2.48	0.10	0.27	215	2.97	5.09	159	0.04	0.13	C64-68,69	
野性	Bladder	394	3.73	9.00	2.61	0.05	0.19	m	160	2.79	0,75	0.01	0.07	C67	
8. HARS	Brain, nervous system	208	2.02	4.92	2.68	0.17	0.27	345	2.00	3.43	1.98	0.12	0.29	79-72, D32-33, D42-43	
₹0.8	Thyroid	29	0.28	0.69	0.32	0.02	0.04	67	0.79	1.35	0,45	0.02	0.03	C73	
ಗಲಕ	Lymphome	406	2.94	9.60	3,96	0.15	0.40	301	4.16	7.13	2.75	0.11	0.30	C81-86,80,90,96	
ea#	Leukemia	251	3.41	8.30	3.87	0.19	0.38	205	2.83	4.05	2.14	0.11	0.21	C91-95,D45-47	
不明及其他导致物情	Other and unupecified	443	4.30	10.47	4.28	0.21	0.45	384	6.30	9.09	3.38	0.14	8.30	A_0	
行政的过去计	Al sites	10304	100.00	243.62	97.04	4.31	10.66	7240	100.00	\$71.46	64.54	2.91	6.68	C03-56	
将常彩空融升度祭	All sites but C44	10240	99.46	242.29	96.54	4,29	10.63	7266	99.52	178,63	64.35	2.91	6.67	C00-96 eec.C44	

Flat file target format

headers

1.1	6	D	1 E				E		×	11		.79	0	P	0
v					Aug Preix	-sec/105	work(30	Corr. Hein	Gam, Bater		deaths.	Cruile	458	Gurn.Nekn	Caro, Balter
territory [NII	atte CN	site (Nil	gendet	Incidence	- 4	1-000	0000-1	760-04	180.74	the state of	From In	Looker (School	and shares	10.0.04	in 0.14
thriting Shi	口腔标识:()):():():():():():():():():():():():()	Ond carety ill phonyes est amonghement	Male	479	1.64	0.10	2.07	1.41	9.11	173	3.67	4.05	1.5.	0.17	0.18
Beijing Shi	鼻射導	Nampharms.	Male	.46	0.29	1.08	0.61	8:04	0.00	86	0.04	1.50	0.00	86.08	0.09
Desireg Shi	市省	Ecologie	Male	\$18	3.28	13.26	1.11	11.33	3.65	470	+.58	31.11	4.53	8.26	31.50
Deliting SH	=	French.	Main	1124	7.07	26.51	11.84	11.62	140	948	8.11	32.00	2.49	0.11	0.78
Delling Ski	·结直祭伯(7)	Colos, rectuto & sume	Main	2318	14.53	12.75	25.61	1.40	3.13	1180	11.48	27.90	10.37	0.41	1.09
(Willing SH)		Liver	Male	3187	6.40	24.94	11.0	16.87	1.37	997	9.69	22.19	10.17	0.67	(2)
Beijing Shi	肥實及其相	Galbiadder etc.	Main	313	2.06	7.81	1.24	0.15	0.39	313	3.04	7.40	2.98	0.14	0.13
finding Sta	原語	Tamora	Male	525	3.30	42.41	5.34	0.36	10.61	464	4.54	13.96	16.68	0.23	0.09
Beijing Shi	4	Leres	Male	256	0.98	3.69	1.89	:0.13	0.28	91	0.88	2.15	0.87	0.04	0.11
Reging Shi	气管皮气管、器	Trachen, broacline it beg	Male	1609	22.76	\$5.33	17.94	1.83	4.82	A126	29.41	7144	25.66	1.11	3.45
Beijing Ski	其他的胸腔器官	Other threads' regard	Male		0.42	1.58	1.0	1106	9.09	.43	6.42	1.92	0.81	1100	0.08
Reging Shi	Transition	Bow	Male	37	0.38	1.18	1.31	0.08	0.10	- 28	0.34	0.03	8.41	0.02	0.05
Orting Still	波動的原始素成	Metamonia of skin	Male	- 24	0.19	0.57	0.31	0.00	0.04	22	0.23	0.51	0.22	0.00	0.63
Deling SA	2.0	Brust	Mate	22	N/	310	8.13	0.02	0.04	.7	0.01	0.17	0.06	0.09	0.01
Dogorg Shi	子道理	Certin and	Main			ale	-	-		-	1.	-	-	مالك	
Selling Shi	于高体发子宫部位于明	United & surger field.	Male	-	-	-	-	-		-	vla	le	de	ath	S
Beiling Std	1110	Ovary Process		1108		1.0.0	Inter	0.42	1.48	215	3.00	12.29	1.0	0.04	8.24
Deling Shi	81968	Tom	Male	34	In	cid	en	ce	3.00	100	0.01	14.27	144	0.05	- 0.01
Desirg SH	#2.00F系统干部	Either & superified minary sepan	Main	043	14	uiu		UC	1.00	280	111	6.62	1.48	0.04	8.27
Beijing Shi	第三日 かんたく 中川	Radies & suprided short repair	Main	817	3.14	18.12	1.01	-0.15	0.95	-	1.73	0.04	245	0.05	0.19
Beijing Shi	E. WALLER	Terms, sectores pyress	Male	104	148	9.13	8.06	0.43	0.55	208	1.02	4.02	145	0.17	0.27
Beiling Shi	ALC: INCLUSION	Theread .	Male	818	8.15	18.34	14.70	1.20	1.28	28	0.28	0.48	8.32	0.02	0.04
Beiging Shi	神色爆	1 readouts	Male	512	1.47	13.05	6.45	8.14	0.76	105	1.64	9.50	196	8.15	0.43
Beijing SH	005	Lokess	Male	495	2.88	29.71	8.75	0.48	0 AT	392	3.43	8.40	1.42	0.19	0.18
theijing Shi	不明历其他所作新闻	Other and mappediled	Male	747	4.78	17.84	10	0.50	0.98	443	4.30	18.47	4.28	0.22	6.45
Desing 584	所有部位合计	All sters	Male	17096	108.00	175.03	182.44	10.27	21.29	10304	108-01	245.62	97.04	+33	10.48
Belling Ski	所有到口前外皮肤	All also ba C44.	Male	1		171.45	100.00	101.14		10221	22.40	247.29	24.74	4.22	12.42
(holying Shi	口腔和影响(除外基层中)	Ond carity & photon on anotherper	Terrain	181	0.07	3.81	1.82	0.13	0.21		3.00	4.75	0.74	8.52	10.01
Design of the	黑粉斑	Nampharyta	female	22	0.13	0.52	0.28	8.00	0.05	22	6.16	0.52	0.22	6.62	9.02
Beijing Ski	#W	Entphagee	Herraie	118	0.10	179	8.87	11.12	18.07	128	1.77	101	0.02	8.09	10.08
BeSing Shi	11	Brench	Fertualie	277	1.49	13.66	6.21	10.17	0.70	382	7.41	9.28	3.47	1.16	0.15
Telling Shi	(結真析(1)))	Colos, rentum & mas	Terraie	1896	10.94	42.11	11.47	0.92	2.01	887	12.84	28.99	8.75	0.24	0.62
Beijing Ski	新報		Fernale	+++	2.68	38.51	4.08	0.07	0.47	4073	8.87	9.54	3.46	0.12	9.37
Delling SM	加興品其他	Contraction to:	Female	297	184	7.08	2.63	0.19	0.28	280	1.87	6.67	3.00	108	0.21
Helping Shi	原目	Passing	Female	+46	1.71	38.41	3,00	0.16	0.46	442	6.30	10.47	3.04	0.18	0.45
Delling Shi		Largest	Temat	19	0.12	0.45	9.17	6.09	0.03	18	0.21	0.96	0.11	0.08	0.02
Beijing Shi	代要求代表。并	Titsches booschei it beg	Lemaie	2494	15.16	棘斑	25.09	1.38	3.08	1207	23,58	41.42	11.14	8.47	1.40
Belling SH	其他的解释器官	Other disease organs	Fendle	42	0.18	0.99	9.52	0.03	0.06	21	0.28	0.50	0.22	10.00	0.03
Beijing Ski		Bear	Fertalk	37	0.32	0.00	0.55	0.00	0.06	34	0.47	0.81	0.46	0.02	0.05
Beijing Sta	点别的深些草藏	Melanoma of skin	Fernie	-25	0.16	0.62	11.12	0.00	0.03	29	0.28	8.47	8.28	0.05	0.03
Deling SH	1.00	Breat	Fertale	201	19.90	78.17	100	1.00	0.61	191	1.10	34.76	8.30	0.71	0.95
Beijing Ski	平面强 平面体质子宫部位,不明	Carta and	Temale	828	2.36	9.21		1.90		152			2.08	8.19	0.23
Sugre Shi	中国体系中省即位十两	Units & suprofied Destri-	Fernalli	543	Enr	nn	111.88	1.94	1.25	319	Fer	na	A	1.28	0.18
Deling Shi	100	Dealer	Ferraie	245	E	na	le	17.14	334	343.	C		C	1.76	0.78
Desing Shi	#17d#	Tests	Fernale	-	1.2	-	1		-2-		1.2				-2-
Delling Shi	#240FE64ET#	Editory & norpetified minuty organi-	Ferrale	160	3.42	• 11 br	8.17	10.00	0.74	219	2.07	1.1	1.12	0.04	0.13
Beijing Shi Beijing Shi	# 2020 MIR 1 M	Blable	Temale	282	nc	ICC	enc	D.	0.10	115	dea	ith	Sin	0.05	0.07
Geijing Shi	E. 1942 E.M.	Train actions portion	Terrale	214	IIC	IUC		C.40	0.60	145		1011	1.00	0.12	0.20
Beiling Shi	AL. INTEND.	Ternel	Female	204	12.61	48.28	34.99	1.06	1.36	87	0.79	1.34	2.45	6.62	0.03
Beijing Shi	48.0	3 rephone	Female	440	2.66	88.42	1.00	0.33	0.58	580	4.18	7.13	2.74	8.11	0.30
Beiling Ski	005	Leukeessa	Ferrale	722	1.94	7.60	8.42	8.27	0.45	201	2.83	4.85	2.14	0.11	0.21
Weiging Shi	不明及其後年代新聞	Otion and suspectively	Terraik	748	4.92	17.67	8.76	1.48	0.09	384	9.30	9.09	3.00	0.14	8.30
Desing Shi	所有部位会计	Allates	Testale	10754	108-00	191.08	206.61	14.02	12.29	TIME	100.00	171.44	84.54	2.90	5.42
Delling Shi	所有部位除外世族	All nics ba C44	Tettale	16324	88.68	346.74	201.48	15.95	12.49	7208	89.13	170.67	64.35	2.92	6.67
	and the same of the second			a second second	100.000	100.14		22.70	48.00	1992	11.00	2.00.003			

dreom

	projected cancer drug treated patients (total China coverage rate)	projected cancer drug treated patients (bottom up calculation	difference in results between methodologies
all other sites & unspecified Bladder Bone Brain, Central Nervous system Breast Cervix Uteri Colon, Rectum & Anus			
Esophagus gallbladder etc Kidney & unspecified Urinary organs Larynx Leukemia Lip, oral cavity, Pharynx but Nasopharync Liver Lymphoma Melanoma of skin Nasopharynx Other Thoracic Organs		Up to differe tumor betwee tw method	nce at level en the o
Ovary pancreas Prostate Stomach Testis Thyroid Gland Trachea, bronchus and lung Uteris & unspecified			

.

Whatever the release we use, we will project the data to nowadays

We can use market sales data (IQVIA CHPA + retail or CPA computed in cycle days per tumor) and / or Universe of Physicians (public source) to project patient numbers to 2021

		F大夫在线 www.haodf.com			a i		n in in		(0) 4.5 mil		Filte by †	ers by d tumor),	lepartme province	ent, disease e and city	(cancer	,	
	ALC.			481年 1 1	部務府 心脈 近心府 消息注 〇 検妖院現実夫 -	計画であ 細同曲5 八の内 生の府 の形形 の形えり	1913年1944 1918年1944 1919年1944			A 000 3	日 2111五 力成仮変。好大大府1 音外科 就医指 ● #### @##	指南	- 25 5 44	108	HTHE		
Assess sales of each Oncology dr	ing across t	umors						source FN	AR or Pati	ent records	surveys - all	ll tumors				FMR / na	Volume conversion factor tient records or desk research
Molecule -L1 Oncology PACLITAXEL DOCETAXEL PEMETREXED GIMERACIL+OTERACIL+TEGAFUE CAPECITABINE OXALIPLATIN GEMCITABINE	ATC3 LO1C LO1C LO1B	tumor 1 YR2016	tumor 1 YR2017 % of patient		YR2020	YR2021	tumor 2 YR2016	tumor 2 YR2017			2 tumor 2	tumor 3	tumor 3 YR2017	tumor YR202		other	convert Dosage Units into nb cycles X Dosage units make a chemo cycle (or 30 for continuous treatment)
TACROLIMUS MYCOPHENOLATE MOFETIL RITUXIMAB etc	L04X L04X L01G	Oncol surve or Ele	ck client hist ology patier eys in China lectronic Me nultiple tum	ent record la (IQVIA, ledical Re	rds A, IPSOS)											cus	ecific stomization of IPA sales data

Template for final output

For Province level output, we'll apply Tier II rates from Market Sizing Study as proxy

Tumor			2016 Measuren	- nent projected	to 2021 based on	IQVIA CHPA Ond	ology Drugs Sa	les								
Pancreas																
				Male					Fei	nale				IPSOS market s	sizing study metri	cs
geography	Projected incidence	projecte d nb Yearly patients	projected treated patients	Projected cancer drug treated patients	Projected nb Yearly patients (prevalence)	projected nb deaths	Projected incidence	projected nb Yearly patients	projected treated patients	Projected cancer drug treated patients	Projected nb Yearly patients (prevalence)	projected nb deaths	coverage rate registry vs Population	rate of new patients	treatment rate	cancer drug
Beijing																
Shijiazhuang																
rest of Hebei															proxy Tier II	
Hebei total																
Tianjin																
Shenyang																
rest of Liaoning															proxy Tier II	
Liaoning total																
Ji'nan																
rest of Shandong															proxy Tier II	
Shandong total																
Shanghai																
Hangzhou																
Ningbo																
Wenzhou																
rest of Zhejiang															proxy Tier II	
Zhejiang total																
Chongqing																
Foshan																
Guangzhou																
rest of Guangdong															proxy Tier II	
Guangdong																
Total China																

And you can also consult result by City, **province**, region...

 Deliverable : Excel table (2453 rows with 2017 book, x10 with full scrap) with some pre-filtered pivot tables for client to explore the data, avoiding double counts


channel	ICD-10	geograph.	geography main	Province	region	tumor site	-	Site Gender	incidence	mortality	Yearly nb patie	mortality rati	populatio province n province covert population	coverage	projected project incide v potie.	ed Diagnosis o focus	f Diagnosis label Market sizin studv		rate trea - patie
	C81-96,88,		Fuzhou	Fujian	East	Lymphoma		Male	17	11	19	59.02%		5 0.229645		81 NHL	NHL	91%	1
20 city	C91-C95	Changle	Fuzhou	Fujian	East	Leukemia		Male	13	6	14	41.43%	0.22964	5 0.229645	57	63 ALL	ALL	90%	
.					_ ·														

channel	(Multiple Items) 🐺		channel Site	total CN 🕶 (Multiple 🕶	ms)	
tumor site	Sum of projected Sum of projected nb Yearly patients treated patients	cancer drug treated	tumor site 🗔	incidence	Sum of projected nb Yearly patients	 Sum of projected cancer drug treated patients

Additional data entry on age groups can provide interesting insights

Cancer registry data only

Cancer registry combined with Market Sizing Study



Cost : all the characteristics of a syndicated project

China Cancer Registry data is a public source. You are invited to order the book so you can consult all the data... on paper. Cost, 208 RMB for 2019 book

中国肿瘤登记年报_购买中国肿瘤登记年报相关商品_孔夫子旧书网

https://m.tb.cn/h.4OXxXav?sm=d3b12a 2019中国肿瘤登记年报人民卫生出版社国家癌症中心9787117309707

• Syndicated section of the project

- Complimentary Contribution of L.E.K Healthcare Strategic consulting firm to enable digitalize the China Cancer registry, otherwise only available on paper format
- Carole Gabay Market Analytics Capabilities in partnership with DRCOM:
 - data entry, desk research, design and expertise
 - Projected Incidence, mortality and Prevalence by tumor at city and province level, with 2017 benchmarks for 20 larger cities
- IPSOS Healthcare China 2015 Oncology Market Sizing Study (to be contracted directly with IPSOS)
- Contributions above can be bundled in one single invoice from IPSOS Healthcare
- Customized by client
- Focus on the tumors of focus, to project the patient numbers from 2016 to nowadays, with the input of other secondary market data sources

Carole Gabay Business Analytics Capabilities

In partnership with DRCOM



FOR MORE INFORMATION, PLEASE VISIT WWW.DRCOMGROUP.COM



Shanghai, PR China E-mail : carole.gabay@drcomgroup.com Tél : 158 2198 1284 We chat : carolegabay

